Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

ClinicoEconomics and Outcomes Research

Volumn 7, Issue , 2015, Pages 313-323

  Schuetz, Charles Andy ^a   Ong, Siew Hwa ^b   Blüher, Matthias ^c  

^a EVIDERA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cardiovascular; Dpp 4 inhibitors; Simulation

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADULT; ARCHIMEDES MODEL; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT RESPONSE; VALIDATION PROCESS;

EID: 84936881674     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S75935     Document Type: Article

References (30)

1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892.
2. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Diabetes Mellitus – Evaluating, Cardiovascular Risk in New, Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, MD, USA: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2008.
3. Byar D P, Simon RM, Friedewald WT, et al. Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med. 1976;295(2): 74–80.
4. Chan KE, Thadhani R, Lazarus JM, Hakim RM. Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc Nephrol. 2010;5(5):856–866.
5. Gersch W, Eddy DM, Dong E. Cardia arrhythmia classifcation: a heart-beat interval-Markov chain approach. Comput Biomed Res. 1970;3(4):385–392.
6. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143(4):251–264.
7. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no 68). Diabetologia. 2004;47(10):1747–1759.
8. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–1933.
9. Kengne A P, Patel A, Colagiuri S, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia. 2010;53(5):821–831.
10. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1): S5–S26.
11. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27–S40.
12. Michigan Model for Diabetes, 2009. Available from: http://www.med.umich.edu/mdrtc/cores/DiseaseModel/model.htm. Accessed April 1, 2015.
13. Barhak J, Isaman DJ, Ye W, Lee D. Chronic disease modeling and simulation software. J Biomed Inform. 2010;43(5):791–799.
14. Grant D, Foos V, Palmer J, Lloyd A, Evans M, McEwan P. Long-term validation of the IMS CORE Diabetes Model in Type 1 and Type 2 diabetes. Presented at: The 72nd Scientifc Sessions of the American Diabetes Association (ADA), June 8–12, 2012, Philadelphia, PA, USA.
15. Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl. 1999;71:S222–S226.
16. Tuttle KR. Charting new territory by simulated modeling of a clinical trial. Clin J Am Soc Nephrol. 2010;5(5):750–752.
17. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162(5):818–825. e816.
18. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
19. Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care. 2003;26(11):3102–3110.
20. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care. 2003;26(11):3093–3101.
21. Archimedes, Inc. Healthcare Modeling. San Francisco, CA: Archimedes, Inc. Available from: http://archimedesmodel.com/. Accessed April 1, 2015.
22. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems – the mathematical formulation. J Biomed Inform. 2002;35(1):37–50.
23. Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. J Med Econ. 2012;15(6):1118–1129.
24. van Herick A, Schuetz CA, Alperin P, Bullano MF, Balu S, Gandhi S. The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model. Clinicoecon Outcomes Res. 2012;4:337–347.
25. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev. 2013;29(5):417–426.
26. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target,7% with eight classes of antidi-abetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab. 2012;14(3): 228–233.
27. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223): 1492–1495.
28. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1): 14–25.
29. White WB, Cannon C P, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14): 1327–1335.
30. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014; 2(6):573–582.